Igixon (Desogestrel, Ethinylestradiol)

Desogestrel is a progestin that inhibits the mid‑cycle surge of luteinizing hormone, preventing ovulation. Ethinylestradiol is a synthetic estrogen that stabilizes the endometrial lining and thickens cervical mucus, making it hostile to sperm. Together they create hormonal conditions that block fertilization and implantation.

The dosing regimen for Igixon is determined by the prescribing clinician. Typically, combined oral contraceptives are taken as one tablet daily for 21 or 24 days followed by a hormone‑free interval, but the exact schedule, tablet strength and any break days must be set by the healthcare provider based on the product label and patient needs.

Igixon is contraindicated during pregnancy because its purpose is to prevent conception. If pregnancy occurs, the product should be discontinued. Limited data are available for breastfeeding; combined oral contraceptives are generally considered compatible with lactation, but clinicians should evaluate individual risk‑benefit and discuss with the patient.

To place an order, submit an enquiry on the Igixon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and the necessary import documentation.

Igixon contains desogestrel, a third‑generation progestin, combined with ethinylestradiol, which may offer a lower risk of androgenic side effects such as acne compared with older progestins. Efficacy in preventing pregnancy is comparable to other approved combined pills, while the side‑effect profile may differ slightly, especially regarding weight gain and lipid changes.

Igixon tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use tablets that are discolored, broken or past the expiration date.

Igixon is taken orally, usually once daily at the same time each day, with or without food. The typical regimen involves a series of active tablets followed by a hormone‑free interval, after which a new pack is started. Patients should follow the specific instructions provided by their prescriber or the product labeling.

The most serious risks include venous thromboembolism, arterial thrombosis such as stroke or myocardial infarction, and severe hypertension. These events are rare but can be life‑threatening, especially in women who smoke, are over 35, or have a history of clotting disorders. Prompt medical attention is required if symptoms of blood clots appear.

Igixon is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or are smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to desogestrel, ethinylestradiol or any excipients in the tablet.